Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice

被引:14
|
作者
Sasu, BJ [1 ]
Hartley, C [1 ]
Schultz, H [1 ]
McElroy, P [1 ]
Khaja, R [1 ]
Elliott, S [1 ]
Egrie, JC [1 ]
Browne, JK [1 ]
Begley, CG [1 ]
Molineux, G [1 ]
机构
[1] Amgen Inc, Dept Hematol, Thousand Oaks, CA 91320 USA
关键词
Aranesp (R); darbepoetin alfa; epoetin alfa; erythropoietic units; hemoglobin;
D O I
10.1159/000084446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The unit of erythropoietic activity has long been the standard by which erythropoietic agents are judged, but the development of long-acting agents such as darbepoetin alfa has highlighted the shortcomings of this approach. To this point, we compared the in vivo activity of Epoetin alfa and darbepoetin alfa per microgram of protein core. Using the established mass-to-unit conversion for Epoetin alfa (1 mu g congruent to 200 U), we then calculated darbepoetin alfa activity in units. Activity varied with treatment regimen (1 mu g darbepoetin alfa congruent to 800 U for 3 times weekly dosing to 8,000 U for a single injection). This analysis reveals the inadequacy of evaluating darbepoetin alfa activity in terms of standard erythropoietic units. We therefore propose that for molecules with heightened biological activity, a more legitimate basis for comparison is the protein mass. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:163 / 174
页数:12
相关论文
共 12 条
  • [11] Differences in Proportion of N-acetyllactosamine and O-acetylated Sialic Acid Have No Significant Effect on the Pharmacokinetics and Biological Activity of Darbepoetin Alfa
    Won Jeong Lee
    Hookeun Oh
    Inseong Choi
    Keunho Lee
    Hyunwoo Shin
    Yoon Jung Lee
    Jeehye Park
    Yoo Hee Yang
    Gyong-Sik Ha
    Dong-Eok Lee
    Kang-Yell Choi
    Eunyoung Choi
    Biotechnology and Bioprocess Engineering, 2022, 27 : 244 - 252
  • [12] Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
    Jeon, Inseung
    Oh, Jaeseong
    Kwon, Yu-Kyung
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Jang, In-Jin
    Yu, Kyung-Sang
    Lee, SeungHwan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 1735 - 1747